|
[1]中华医学会.丙型肝炎防治指南[J].中华肝脏病杂志, 2004, 12 (4) :194-198.
|
|
[2]Lavanchy D.The global burden of hepatitis C[J].Liver Int, 2009 (29) :74-81.
|
|
[3]Armstrong GL, Wasley A, Simard EP, et al.The prevalence of hepati-tis C virus infection in the United States, 1999through2002[J].Ann Intern Med, 2006, (144) :705-714.
|
|
[4]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, manage-ment, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.
|
|
[5]Seeff LB.Natural history of chronic hepatitis C[J].Hepatology, 2002, 36 (5Suppl1) :S35-S46.
|
|
[6]D'souza R, Glynn MJ, Ushiro-Lumb I, et al.Prevalence of hepa-titis C-related cirrhosis in elderly Asian patients infected in child-hood[J].Clin Gastroenterol Hepatol, 2005, 3 (9) :910-917.
|
|
[7]Kobayashi S, Takeda T, Enomoto M, et al.Development of hepato-cellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy:a multicenter, retrospective cohort study of1124patients[J].Liver Int, 2007, 27 (2) :186-191.
|
|
[8]Gerlach JT, Diepolder HM, Zachoval R, et al.Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clear-ance[J].Gastroenterology, 2003, 125 (1) :80-88.
|
|
[9]Veldt BJ, Heathcote EJ, Wedemeyer H, et al.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis[J].Ann Intern Med, 2007, 147 (10) :677-684.
|
|
[10]Deuffic-Burban S, Deltenre P, Louvet A, et al.Impact of viral eradi-cation on mortality related to hepatitis C:a modeling approach in France[J].J Hepatol, 2008, 49 (2) :175-183.
|
|
[11]George SL, Bacon BR, Brunt EM, et al.Clinical, virologic, histo-logic, and biochemical outcomes after successful HCV therapy:a5-year follow-up of150patients[J].Hepatology, 2009, 49 (3) :729-738.
|
|
[12]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatitis C virus infection[J].J Hepatology, 2011, 55 (2) :245-264.
|
|
[13]Mchutchison JG, Lawitz EJ, Shiffman ML, et al.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection[J].New Engl J Med, 2009 (361) :580-593.
|
|
[14]Rumi MG, Alessio aghemo A, Prati GM, et al.Randomized study ofpeginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C[J].Gastroenterology, 2010, 138 (1) :108-115.
|
|
[15]Jacobson IM, Brown RJ, Freilich B, et al.Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C pa-tients:a randomized trial[J].Hepatology, 2007, 4:971-981.
|
|
[16]Lam KD, Trinh HN, Do ST, et al.Randomized controlled trial of pegylated interferon-alfa2a and ribavirin in treatment-naive chro-nic hepatitis C genotype6[J].Hepatology, 2010, 52 (5) :1573-1580.
|
|
[17]Moreno C, Deltenre P, Pawlotsky JM, et al.Shortened treatment dura-tion in treatment-naive genotype1HCV patients with rapid virological response:a meta-analysis[J].J Hepatol, 2010, 52 (1) :25-31.
|
|
[18]Fried MW, Hadziyannis SJ, Shiffman ML, et al.Rapid virological re-sponse is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection[J].J Hepatol, 2011, 55 (1) :69-75.
|
|
[19]Kamal SM, El Kamary SS, Shardell MD, et al.Pegylated interferon alpha-2b plus ribavirin in patients with genotype4chronic hepati-tis C:The role of rapid and early virologic response[J].Hepatolo-gy, 2007, 46 (6) :1732-1740.
|
|
[20]Berg T, von Wagner M, Nasser S, et al.Extended treatment dura-tion for hepatitis C virus type1:comparing48versus72weeks of peginterferon-alfa-2a plus ribavirin[J].Gastroenterology, 2006, 130 (4) :1086-1097.
|
|
[21]Pearlman BL, Ehleben C, Saifee S.Treatment extension to72 weeks of peginterferon and ribavirin in hepatitis c genotype1-in-fected slow responders[J].Hepatology, 2007, 46 (6) :1688-1694.
|
|
[22]Ide T, Hino T, Ogata K, et al.A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype1b chronic hepatitis C[J].Am J Gastroenterol, 2009, 104 (1) :70-75.
|
|
[23]Mangia A, Minerva N, Bacca D, et al.Individualized treatment duration for hepatitis C genotype1patients:A randomized con-trolled trial[J].Hepatology, 2008, 47 (1) :43-50.
|
|
[24]Manns M, Zeuzem S, Sood A, et al.Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype2and3chronic hepatitis C[J].J Hepatol, 2011, 55 (3) :554-563.
|
|
[25]Ferenci P, Laferl H, Scherzer TM, et al.Peginterferon alfa-2a and ribavirin for24weeks in hepatitis C type1and4patients with rapid virological response[J].Gastroenterology, 2008, 135 (2) :451-458.
|
|
[26]Oze T, Hiramatsu N, Yakushijin T, et al.Indications and limita-tions for aged patients with chronic hepatitis C in pegylated interfer-on alfa-2b plus ribavirin combination therapy[J].J Hepatol, 2011, 54 (4) :604-611.
|
|
[27]Jacobson IM, Brown RS Jr, Mccone J, et al.Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype1[J].Hepatology, 2007, 46 (4) :982-990.
|
|
[28]Bressler BL, Guindi M, Tomlinson G, et al.High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C[J].Hepatology, 2003, 38 (3) :639-644.
|
|
[29]Deltenre P, Louvet A, Lemoine M, et al.Impact of insulin resist-ance on sustained response in HCV patients treated with pegylated interferon and ribavirin:A meta-analysis[J].J Hepatol, 2011, 55 (6) :1187-1194.
|
|
[30]Westin J, Lagging M, Dhillon AP, et al.Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection[J].J Viral Hepat, 2007, 14 (1) :29-35.
|
|
[31]Schaefer M, Hinzpeter A, Mohmand A, et al.Hepatitis C treatment in"difficult-to-treat"psychiatric patients with pegylated interferon-alpha and ribavirin:response and psychiatric side effects[J].Hepa-tology, 2007, 46 (4) :991-998.
|
|
[32]Anand BS, Currie S, Dieperink E, et al.Alcohol use and treatment of hepatitis C virus:results of a National multicenter study[J].Gastroen-terology, 2006, 130 (6) :1607-1616.
|
|
[33]Helbling B, Jochum W, Stamenic I, et al.HCV-related advanced fibrosis/cirrhosis:randomized controlled trial of pegylated interferon alpha-2a and ribavirin[J].J Viral Hepat, 2006, 13 (11) :762-769.
|
|
[34]Carrat F, Bani-Sadr F, Pol S, et al.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients:a randomized controlled trial[J].JA-MA, 2004, 292 (23) :2839-2848.
|
|
[35]Potthoff A, Wedemeyer H, Boecher WO, et al.The HEP-NET B/C co-infection trial:A prospective multicenter study to investi-gate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection[J].J Hepatol, 2008, 49 (5) :688-694.
|
|
[36]Sarrazin C, Susser S, Doehring A, et al.Importance of IL28B gene polymorphisms in hepatitis C virus genotype2and3infected patients[J].J Hepatol, 2011, 54 (3) :415-421.
|
|
[37]Ge D, Fellay J, Thompson AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Na-ture, 2009, 461 (7262) :399-401.
|
|
[38]Rauch A, Kutalik Z, Descombes P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.
|
|
[39]Thomas DL, Thio CL, Martin MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.
|
|
[40]Suppiah V, Moldovan M, Ahlenstiel G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet, 2009, 41:1100-1104.
|
|
[41]Kawaoka T, Hayes CN, Ohishi W, et al.Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes2a and2b[J].J Hepatol, 2011, 54 (3) :408-414.
|
|
[42]Kurosaki M, Tanaka Y, Nishida N, et al.Pre-treatment predic-tion of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors[J].J Hepatol, 2011, 54 (3) :439-448.
|
|
[43]Scherzer TM, Hofer H, Staettermayer AF, et al.Early virologic re-sponse and IL28B polymorphisms in patients with chronic hepatitis C genotype3treated with peginterferon alfa-2a and ribavirin[J].J Hepatol, 2011, 54 (5) :866-871.
|
|
[44]Afdhal NH, Mchutchison JG, Zeuzem S, et al.Hepatitis C phar-macogenetics:state of the art in2010[J].Hepatology, 2011, 53 (1) :336-345.
|
|
[45]Tillmann HL, Patel K, Muir AJ, et al.Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C[J].J Hepatol, 2011, 55 (6) :1195-1200.
|
|
[46]O'brien TR.Interferon-alfa, interferon-λand hepatitis C[J].nature genetics, 2009, 41 (10) :1049-1050.
|
|
[47]Langhans B, Kupfer B, Braunschweiger I, et al.Interferon-lamb-da serum levels in hepatitis C[J].J Hepatol, 2011, 54 (5) :859-865.
|
|
[48]Abe H, Hayes CN, Ochi H, et al.IL28variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy[J].J Hepatol, 2011, 54 (6) :1094-1101.
|
|
[49]Zhang L, Jilg N, Shao RX, et al.IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway[J].J Hepatol, 2011, 55 (2) :289-298.
|
|
[50]Pockros PJ.New direct-acting antivirals in the development for hepatitis C virus infection[J].Therap Adv Gastroenterol, 2010, 3 (3) :191-202.
|
|
[51]Jacobson IM, McHutchison JG, Dusheiko GM, et al.Telaprevir in combination with peginterferon and ribavirin in genotype1HCV treatment-naive patients:final results of Phase3ADVANCE study[J].Hepatology2010;52:427A.
|
|
[52]Sherman KE, Flamm SL, Afdhal NH, et al.Telaprevir in combination with peginterferon alfa2b and ribavirin for24or48weeks in treatment-naive genotype1HCV patients who achieved an extended rapid viral re-sponse:final results of Phase3ILLUMINATE study[J].Hepatology, 2010, 52:401A.
|
|
[53]Zeuzem S, Andreone P, Pol S, et al.Realize trial resuilts:Telapla-previr-based regimen for genotype1hepatitis C virus infection in patients with prior null response, partial response or relapse to Peginterferon/ribavirin[J].J Hepatol, 2011, 54 (Suppl) :S3A.
|
|
[54]Bacon BR, Gordon SC, Lawitz E, et al.HCV RESPOND-2final results:high sustained virologic response among genotype1previous nonresponders and relapsers to peginterferon/ribavirin when retrea-ted with boceprevir plus PegIntron/ribavirin[J].Hepatology, 2010, 52:430A.
|
|
[55]Poordad F, Mccone J, Bacon BR, et al.Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive pa-tients with hepatitis C (HCV) genotype1:SPRINT-2final results[J].Hepatology, 2010, 52:402A.
|
|
[56]Bruno S, Vierling JM, Esteban R, et al.Boceprevir in addition to atandasd of care enhanced SVR in hepatitis C virus (HCV) genotype-1with advanced fibrosis/cirrhosis:Subgroup analysis of SPRINT-2and RESPOND-2studies[J].J Hepatol, 2011, 54 (Suppl) :S4A.
|
|
[57]Ghany MG, Nelson DR, Strader DB, et al.An update on treatment of genotype1chronic hepatitis C virus infection:2011practice guideline by the American Association for the Study of Liver Disea-ses[J].Hepatology, 2011, 54 (4) :1433-1444.
|
|
[58]Ohara E, Hiraga N, Imamura M, et al.Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination thera-py in human hepatocyte chimeric mice[J].J Hepatol, 2011, 54 (5) :872-878.
|
|
[59]Bisceglie AD, Nelson DR, Gane E, et al.1363VX-222with tvralone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis c:zenith study in-terim results[J].J Hepatol, 2011, 54 (Suppl) :S540.
|
|
[60]Lok A, Gardiner D, Lawitz E, et al.1356quadruple therapy with bms-790052, bms-650032and peg-ifn/rbv for24weeks results in100%svr12in hcv genotype1null responders[J].J Hepatol, 2011, 54 (Suppl) :S536.
|
|
[61]Stefan zeuzem ST, Peter angus PA.Efficacy of the protease inhibi-tor BI201335, polymerase inhibitor BI207127, and ribavirin in pa-tients with chronic HCV infection[J].Gastroenterology, 2011, 141 (6) :2047-2055.
|
PDF下载 ( 1108 KB)
本文二维码
下载:
